Merck & Co., Inc. (NYSE:MRK) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Merck & Co., Inc. (NYSE:MRK) had its target price boosted by investment analysts at Wells Fargo & Company from $150.00 to $170.00 in a research note issued on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 12.50% from the stock’s current price.

A number of other brokerages have also recently weighed in on MRK. Daiwa Securities Group raised Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price objective on the stock in a report on Wednesday, August 12th. UBS Group upped their target price on Merck & Co., Inc. from $145.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Argus increased their price target on shares of Merck & Co., Inc. from $145.00 to $170.00 and gave the company a “buy” rating in a research report on Tuesday, August 25th. Guggenheim lifted their price target on shares of Merck & Co., Inc. from $145.00 to $146.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, Morgan Stanley upgraded shares of Merck & Co., Inc. from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $116.00 to $179.00 in a report on Thursday, August 20th. Fifteen investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $148.60.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK traded down $1.23 during mid-day trading on Friday, reaching $151.11. 612,581 shares of the company were exchanged, compared to its average volume of 10,761,100. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $156.92. The company’s 50 day moving average price is $134.20 and its 200 day moving average price is $123.33. The stock has a market capitalization of $372.82 billion, a PE ratio of 120.75, a PEG ratio of 6.60 and a beta of 0.21. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. During the same quarter in the prior year, the firm earned $2.13 earnings per share. The firm’s revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Sell-side analysts forecast that Merck & Co., Inc. will post 2.76 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Jennifer Zachary sold 80,315 shares of the business’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the transaction, the executive vice president owned 45,509 shares in the company, valued at $6,073,631.14. The trade was a 63.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP David Williams sold 52,847 shares of the stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the transaction, the executive vice president directly owned 31,716 shares of the company’s stock, valued at approximately $4,084,069.32. The trade was a 62.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 228,238 shares of company stock worth $29,977,783. Company insiders own 0.17% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Round Rock Advisors LLC raised its holdings in Merck & Co., Inc. by 0.7% in the second quarter. Round Rock Advisors LLC now owns 9,901 shares of the company’s stock worth $1,272,000 after purchasing an additional 66 shares in the last quarter. Cascade Financial Partners LLC lifted its position in Merck & Co., Inc. by 0.5% during the second quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock valued at $1,895,000 after buying an additional 80 shares during the period. Somerset Trust Co boosted its holdings in shares of Merck & Co., Inc. by 0.9% during the 2nd quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock valued at $1,118,000 after buying an additional 81 shares in the last quarter. Stonebridge Financial Group LLC boosted its holdings in shares of Merck & Co., Inc. by 0.9% during the 2nd quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company’s stock valued at $1,124,000 after buying an additional 81 shares in the last quarter. Finally, Stronghold Wealth Management L.L.C. grew its position in shares of Merck & Co., Inc. by 2.6% in the 2nd quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company’s stock worth $416,000 after buying an additional 82 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.